T cell therapy companies develop treatments that use a patient’s own or donor-derived immune cells to recognise and attack disease. These approaches are primarily used in cancer immunotherapy, with emerging applications across autoimmune and infectious diseases.
This category includes companies working on:
Browse 48 UK T cell therapy companies below.
Microfluidic avidity platform for preclinical cell therapy validation
Avigen is a contract research organisation providing preclinical validation services for cellular immunotherapies using a proprietary microfluidic platform. The platform measures cellular avidity, the total binding strength between immune and cancer cells, at high throughput using fluid shear stress, enabling…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform embeds a feedback mechanism into therapeutic biologics that deactivates the drug in response to excessive immune activation, aiming to…
Synthetic T cell-priming vaccines and immunotherapies for infectious disease
Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies. Its nanoparticle platform delivers synthetic peptides that stimulate cellular immune responses against intracellular pathogens, providing strain-agnostic protection without cold-chain…
Next-generation CAR T-cell therapies for solid tumours
ImmunoKey is a seed-stage biotechnology company developing CAR T-cell therapies designed to overcome the barriers limiting efficacy in solid tumours. Its proprietary platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies to enhance T-cell persistence and…
AI-native platform for cell culture process design and optimisation
Tolemy Bio Ltd is a company developing an AI-native platform for cell therapy process development and manufacturing optimisation. The platform ingests experimental and bioreactor data including cell growth, phenotype, potency, and metabolite profiles, then applies causal AI models to identify the biological drivers of…
Multimodal engineered T-cell therapies for treatment-refractory solid cancers
Alceus Bio is a biotechnology company developing next-generation engineered T-cell therapies for solid tumours. Its platform uses generative AI and synthetic biology to design therapeutic proteins that patient-derived immune cells are programmed to express and deliver in situ, targeting intracellular disease drivers…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis, type 1 diabetes and inflammatory bowel disease. The company reprograms pathogenic T cells into homeostatic, anti-inflammatory cells directly…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to engineer Tregs with enhanced persistence and potency. Its lead candidate QEL-001 is in the Phase 1/2 LIBERATE trial for liver transplant…
Lentiviral vector platform improving yield for advanced cell therapies
Lentitek is a biotechnology company developing proprietary lentiviral vector manufacturing technology for cell and gene therapy developers. Its platform uses novel promoter engineering to reduce unwanted payload gene expression in manufacturing cell lines, improving vector yield, quality and potency. The technology…
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…
Hypoxia-activated CAR-T cell therapy platform for solid tumour cancers
Korecyte Bio is a preclinical-stage cell therapy company developing HypoxiCAR, a modular CAR-T platform for treating solid tumours. The technology uses a dual-sensor genetic switch that keeps engineered T-cells dormant in healthy tissue and activates them only within the low-oxygen environment typical of solid…
Full-service CRO for Phase I–IV pharmaceutical and device trials
Clinicology is a contract research organisation providing clinical trial management services to pharmaceutical, biotechnology, and medical device companies. Services span site startup, monitoring, project management, regulatory submissions, patient recruitment, medical monitoring, medical writing, and…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter. Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel…
Immune cell separation and expansion platform for cell therapies
CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation, and expansion in a single workflow. The system exploits the natural migratory behaviour of immune cells across membranes, replacing…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions, and cancer. Its pipeline is built on four proprietary viral vector and synthetic immunotherapy platforms and includes clinical candidates…
Specialist immunology CRO for preclinical biotherapeutic drug discovery
RoukenBio is a specialist contract research organisation providing preclinical immunology services to biopharmaceutical companies worldwide. Its team offers cell-based bioassay development, functional characterisation of antibody therapeutics and complex biologics, cell line engineering, and CMC-quality potency assay…
Individualised neoantigen-based cell therapies for ovarian and solid cancers
Singula Bio is a seed-stage biotechnology company developing individualised, neoantigen-based cell therapies for patients with solid tumours, with an initial focus on ovarian cancer and other difficult-to-treat malignancies. The company's approach harnesses a patient's own immune system to target mutations that appear…
Biomimetic cell culture platform for reproducible cell therapy development
Stembond Technologies is a Cambridge University spin-out developing a synthetic, mechanically tuned biomimetic substrate that replicates the physical properties of human tissue microenvironments. The platform delivers reproducible cell culture conditions, reducing phenotypic drift and improving consistency across…